Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
RNA

RNA - Avidity Biosciences Inc Stock Price, Fair Value and News

$72.47-0.17 (-0.23%)
Market Closed

18/100

RNA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

18/100

RNA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$58.08

Target 3M

$65.34

Target 6M

$61.71

RNA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RNA Price Action

Last 7 days

-0.2%

Last 30 days

0.4%

Last 90 days

4.0%

Trailing 12 Months

125.9%

RNA RSI Chart

RNA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RNA Valuation

Market Cap

10.9B

Price/Earnings (Trailing)

-19.86

Price/Sales (Trailing)

170.8

Price/Free Cashflow

-18.44

RNA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$58.08

Target 3M

$65.34

Target 6M

$61.71

RNA Fundamentals

RNA Revenue

Revenue (TTM)

63.9M

Rev. Growth (Yr)

-17.94%

Rev. Growth (Qtr)

1.84%

RNA Earnings

Earnings (TTM)

-549.8M

Earnings Growth (Yr)

-116.97%

Earnings Growth (Qtr)

-10.89%

RNA Profitability

Return on Equity

-29.15%

Return on Assets

-25.76%

Free Cashflow Yield

-5.42%

RNA Investor Care

Shares Dilution (1Y)

26.29%

Diluted EPS (TTM)

-4.18

RNA Alerts

  • 8 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202564.6M67.2M63.9M0
202430.3M36.4M51.6M56.9M
20238.7M13.9M14.2M27.3M
20227.8M6.8M5.9M5.0M
20218.1M9.2M9.6M8.7M
20203.7M5.0M6.1M6.8M
201901.0M1.7M2.3M
2018000379.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Avidity Biosciences Inc

RNA
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease is under phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of Duchenne Muscular Dystrophy, which is under phase 1/2 clinical trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy is in phase 1/2 clinical trial. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
 CEO
 WEBSITEaviditybiosciences.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES186

Avidity Biosciences Inc Frequently Asked Questions

RNA is the stock ticker symbol of Avidity Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Avidity Biosciences Inc is 10.92 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check RNA's fair value in chart for subscribers.

The fair value guage provides a quick view whether RNA is over valued or under valued. Whether Avidity Biosciences Inc is cheap or expensive depends on the assumptions which impact Avidity Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RNA.

As of Wed Jan 28 2026, RNA's PE ratio (Price to Earnings) is -19.86 and Price to Sales (PS) ratio is 170.8. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RNA PE ratio will change depending on the future growth rate expectations of investors.